Saturday, November 8, 2025

Champignon Closes AltMed Transaction, Partners With Leading Canadian Pharmacy

Champignon Brands (CSE: SHRM) today announced that it has partnered with a major pharmacy chain within Canada to dispense its ketamine topical prescription product throughout the network. While the pharmacy chain was not addressed by name, it is said to be one of the leading chains within the country.

Under the arrangement, Champignon will see the pharmacy perform central fill and compounding functions for the firms proprietary ketamine formulations at one location. The products will then be distributed as needed throughout the pharmacies network of locations. Champignon will be utilizing this network to also distribute its products to numerous medical and pain and addiction clinics throughout the nation.

In connection with the arrangement, Champignon and the pharmacy have begun to design a custom level “B” clean room which will be used to compound and package the ketamine formulations, which is expected to be completed by the third quarter of 2020. Such formulations include off-market intranasal esketamine and ketamine topicals.

“With this arrangement, Champignon boasts complete vertical integration with respect to our rapid onset ketamine treatments and therapies. From novel formulations to product development at a purpose-built GMP and DIN licensed pharmaceutical facility, and now automated prescription fulfillment and on-site compounding infrastructure, we have managed to capture the entire product lifecycle.”
Gareth Bridsall, CEO

Outside the developments of Champignon’s ketamine formulations, the company also announced that it has closed the transaction with that of AltMed Capital Corp. AltMed operates a ketamine clinic in Ontario known as the Canadian Rapid Treatment Centre of Excellence (CRTCE), for which it recently acquired 100% of, in addition to being a psychedelic medicine IP aggregator and novel drug discoverer.

Champignon currently intends to open five additional ketamine clinics across North America by the fourth quarter of 2020, with locations planned for New York, California, and Florida.

Champignon Brands last traded at $0.88 on the CSE.


FULL DISCLOSURE: Champignon Brands is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Champignon Brands on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

One Response

Video Articles

New Gold Q3 Earnings: Cranking Out Cash Flow

Agnico Q3 Earnings: Critical Minerals Come Into Focus

Newmont Q3 Earnings: The Free Cash Flow King – For Now

Recommended

PTX Metals Compiles Geophysical Data For W2 Project Following Magnetic Survey

Altamira Gold Sees Aura Minerals Increase Stake To 18.2%

Related News

Champignon Brands Appoints Dr Joseph Gabriele To Special Advisory Committee

Champignon Brands (CSE: SHRM) this morning announced that it is bolstering its special advisory committee...

Wednesday, March 25, 2020, 08:57:50 AM

Champignon Brands Latest Shroom Stock To IPO

Champignon Brands (CSE: SHRM) completed its initial public offering (IPO) late Friday night, with the...

Monday, March 2, 2020, 10:40:37 AM

Champignon Brands Appoints Dr Roger McIntyre As CEO

Champignon Brands (CSE: SHRM) this morning announced that it has named Dr Roger McIntyre as...

Monday, May 11, 2020, 09:48:09 AM

Braxia Scientific Launches Multiple-Dose Psilocybin Clinical Trial for Treatment-Resistant Depression

Braxia Scientific Corp. (CSE: BRAX), formerly Champignon Brands, announced today that its clinical research and...

Friday, August 27, 2021, 08:20:00 AM

Champignon Brands To Acquire Biotech Firm Novo Formulations

Champignon Brands (CSE: SHRM) announced today that they have signed a definitive agreement to acquire...

Thursday, March 19, 2020, 03:27:32 PM